Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
170.69
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
↗
Today 8:23 EST
Via
MarketBeat
2 Healthcare Stocks to Buy for 2026 and Beyond
↗
Today 5:35 EST
These could be the next biotech giants.
Via
The Motley Fool
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...
Via
MarketMinute
Here are the top movers in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Where Axsome Therapeutics Stands With Analysts
↗
August 04, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
A Look at Axsome Therapeutics's Upcoming Earnings Report
↗
August 01, 2025
Via
Benzinga
Why Axsome Therapeutics Stock Rocketed Higher to End 2025
↗
December 31, 2025
Axsome Therapeutics shareholders got a New Year's gift from the FDA.
Via
The Motley Fool
The market is filled with gapping stocks in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy
↗
December 31, 2025
AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain.
Via
Stocktwits
2 Under-the-Radar Stocks to Buy Heading Into 2026
↗
December 01, 2025
These drugmakers are poised to profit from their innovative engines.
Via
The Motley Fool
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
December 11, 2025
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Emissions
Axsome (AXSM) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Axsome (AXSM) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
2 Monster Stocks in the Making
↗
November 10, 2025
There might still be time to get in on the ground floor.
Via
The Motley Fool
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss
↗
November 03, 2025
Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss.
Via
Chartmill
Uncovering Potential: Axsome Therapeutics's Earnings Preview
↗
October 31, 2025
Via
Benzinga
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
↗
September 30, 2025
Both should have significant catalysts by the end of the decade.
Via
The Motley Fool
Pharma Tariffs Back In Spotlight On New Trump Threat
↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports.
Via
Investor's Business Daily
Topics
ETFs
Government
World Trade
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
↗
September 04, 2025
Both companies have made significant progress in recent years.
Via
The Motley Fool
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts
↗
September 03, 2025
Via
Benzinga
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
↗
August 18, 2025
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.
Via
Benzinga
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
↗
August 05, 2025
Via
Benzinga
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading
↗
August 04, 2025
Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS.
Via
Chartmill
Axsome (AXSM) Q2 Revenue Soars 72%
↗
August 04, 2025
Via
The Motley Fool
Topics
Intellectual Property
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
↗
July 24, 2025
Via
The Motley Fool
Where Axsome Therapeutics Stands With Analysts
↗
July 03, 2025
Via
Benzinga
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
↗
June 09, 2025
The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.
Via
Benzinga
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
↗
June 09, 2025
Via
Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability
↗
June 09, 2025
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.
Via
Stocktwits
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
